选择性口服BTK抑制剂瑞米布替尼治疗干燥综合征的疗效与安全性:一项随机双盲安慰剂对照2期试验结果
这项2期随机双盲安慰剂对照试验纳入符合2016年ACR/EULAR干燥综合征分类标准、抗Ro/SSA抗体阳性且ESSDAI≥5、ESSPRI≥5的中重度干燥综合征患者,评估瑞米布替尼100 mg每日一次或两次给药24周的疗效与安全性。结果显示瑞米布替尼较安慰剂显著改善ESSDAI评分(ΔESSDAI -2.86,p=0.003),但ESSPRI无治疗效应(ΔESSPRI 0.17,p=0.663),安全性良好。
要点
- 瑞米布替尼较安慰剂显著改善24周ESSDAI评分,ΔESSDAI -2.86(p=0.003)。
- ESSPRI未见治疗效应,ΔESSPRI 0.17(p=0.663)。
- 非刺激唾液流率呈改善趋势,24周安全性良好。
核心结论
- 2期试验数据显示瑞米布替尼对干燥综合征具有初步疗效和良好安全性。
研究设计与样本
- 2期随机双盲安慰剂对照试验(NCT04035668;LOUiSSE研究),纳入符合2016年ACR/EULAR干燥综合征分类标准、抗Ro/SSA抗体阳性、ESSDAI≥5且ESSPRI≥5的中重度干燥综合征患者,接受瑞米布替尼100 mg每日一次或两次或安慰剂治疗24周。
主要发现
- 瑞米布替尼较安慰剂显著改善24周ESSDAI评分,ΔESSDAI -2.86(p=0.003)。
- ESSPRI评分未见治疗效应,ΔESSPRI 0.17(p=0.663)。
- 瑞米布替尼较安慰剂在24周内非刺激唾液流率呈改善趋势。
- 瑞米布替尼在干燥综合征患者中24周安全性良好。
- 瑞米布替尼较安慰剂引起血液基因表达和血清蛋白丰度的显著变化。
关键数值与推荐
- 主要终点为第24周ESSDAI较基线的变化。
- 关键次要终点包括ESSDAI随时间较基线的变化、ESSPRI随时间较基线的变化及瑞米布替尼在干燥综合征中的安全性。
- 关键探索性终点包括唾液流率、可溶性生物标志物、血液转录组和血清蛋白质组谱的变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the safety and efficacy of remibrutinib in patients with moderate-to-severe Sjögren's syndrome (SjS) in a phase 2 randomised, double-blind trial (NCT04035668; LOUiSSE (LOU064 in Sjögren's Syndrome) study). METHODS: Eligible patients fulfilling 2016 American College of Rheumatology/European League Against Rheumatism (EULAR) criteria for SjS, positive for anti-Ro/Sjögren's syndrome-related antigen A antibodies, with moderate-to-severe disease activity (EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) (based on weighted score) ≥ 5, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) ≥ 5) received remibrutinib (100 mg) either one or two times a day, or placebo for the 24-week study treatment period. The primary endpoint was change from baseline in ESSDAI at week 24. Key secondary endpoints included change from baseline in ESSDAI over time, change from baseline in ESSPRI over time and safety of remibrutinib in SjS. Key exploratory endpoints included changes to the salivary flow rate, soluble biomarkers, blood transcriptomic and serum proteomic profiles. RESULTS: Remibrutinib significantly improved ESSDAI score in patients with SjS over 24 weeks compared with placebo (ΔESSDAI -2.86, p=0.003). No treatment effect was observed in ESSPRI score (ΔESSPRI 0.17, p=0.663). There was a trend towards improvement of unstimulated salivary flow with remibrutinib compared with placebo over 24 weeks. Remibrutinib had a favourable safety profile in patients with SjS over 24 weeks. Remibrutinib induced significant changes in gene expression in blood, and serum protein abundance compared with placebo. CONCLUSIONS: These data show preliminary efficacy and favourable safety of remibrutinib in a phase 2 trial for SjS.
引用
- Dörner T, Kaul M, Szántó A, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis. 2024. PMID: 37932009. doi:10.1136/ard-2023-224691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。